Saturday 17 October 2026
Export RGNX’s income statement to Excel — free account
REGENXBIO Inc.
RGNX Healthcare Biotechnology
REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024. In the quarter to June 2026, revenue grew 405.7%, EPS grew 131.2% and free cash flow fell 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.93
0.23
−3.21%
Follow RGNX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.09 | 4.36 | 5.00 | 3.63 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.91) | (14.20) | (5.77) | (10.17) | |
P/B ratio |
3.09 | 7.23 | 20.84 | 8.82 | |
Price to Tangible BV |
3.09 | 7.23 | 20.84 | 8.82 | |
EV/Sales |
1.43 | 3.04 | 3.36 | 3.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.23) | (4.18) | (1.26) | (2.16) | |
EV/FCF |
(2.17) | (4.10) | (1.25) | (2.13) | |
Quick Ratio |
2.40 | 2.17 | 2.26 | 2.57 | |
Current Ratio |
2.66 | 2.38 | 2.62 | 2.86 | |
Net Debt/EBITDA |
5.95 | 4.28 | 1.87 | (3.25) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.31 | 0.37 | 0.21 | 0.36 | |
Operating CF/Net income |
0.90 | 0.78 | 0.85 | (2.74) | |
Capex/Depreciation |
(0.08) | (0.13) | (0.41) | (0.23) | |
Interest Coverage |
(3.98) | (4.69) | (9.57) | 3.76 | |
Research and Development Expense of Revenue |
188.68% | 196.50% | 896.90% | 51.92% | |
Selling, General and Administrative Expense of Revenue |
68.12% | 73.77% | 333.27% | 20.01% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
30.26% | 27.61% | 134.79% | 8.38% | |
Graham Net Nets |
(0.06) | (0.09) | (0.31) | (0.12) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(35.96%) | (26.11%) | (66.83%) | (31.64%) | |
Free Cash Flow Yield |
(21.31%) | (17.02%) | (53.81%) | (39.46%) | |
Revenue per Share |
0.58 | 0.59 | 0.12 | 2.05 | |
Operating CF per Share |
(1.08) | (1.01) | (1.45) | (1.18) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(1.09) | (1.02) | (1.48) | (1.19) | |
Cash per Share |
5.30 | 4.46 | 2.87 | 2.00 | |
Shareholders Equity per Share |
3.12 | 1.99 | 0.40 | 1.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.12 | 1.99 | 0.40 | 1.36 | |
Free Cash Flow |
(56.45) | (52.80) | (77.42) | (63.00) | |
Working Capital |
207.40 | 163.19 | 115.41 | 153.54 | |
Capital Expenditures |
(0.49) | (0.51) | (1.23) | (0.76) | |
Net Current Asset Value |
(31.78) | (69.02) | (134.30) | (78.70) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.19 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
24.48 | 23.43 | 14.12 | 63.48 | |
Average Payables |
20.89 | 22.08 | 20.13 | 18.60 | |
Average Assets |
522.16 | 459.51 | 416.41 | 483.82 | |
Average Common Equity |
231.43 | 181.19 | 147.64 | 142.72 |
Columns are period end dates